Abiomed Press Release on Death of James Quinn
James Quinn, AbioCor Recipient, Dies at Hahnemann University Hospital
Abiomed Press Release on Death of James Quinn Abiomed: AbioCor Clinical Trial Media Center
ABIOMED, Inc. (NASDAQ:ABMD) today reported that Hahnemann University Hospital has announced that Mr. James Quinn, who received an AbioCor™ Implantable Replacement Heart at Hahnemann University Hospital in Philadelphia, Pennsylvania on November 5, 2001, suffered a fatal stroke on Friday, August 23rd . Despite efforts to improve his condition, he became unresponsive that evening and was withdrawn from life support today.
"We are deeply saddened by Mr. Quinn's passing," said Dr. Robert T.V. Kung, ABIOMED's Senior Vice President and Chief Scientific Officer. "Our thoughts are with the Quinn family and James' many friends. Everyone at ABIOMED has the utmost respect for the courage, tenacity and will to live that James exemplified. We are thankful for the contribution he has made, and for the opportunity to know him."
In accordance with Company policy designed to respect patient privacy rights throughout the course of the AbioCor clinical trial, ABIOMED will have no further comment at this time.
The hospital's press release may be viewed at www.hahnemannheart.com or www.drexel.edu.
Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's AbioCor Implantable Replacement Heart is being implanted in patients as part of an initial clinical trial conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS, a heart assist device for the temporary support of all patients with failing but potentially recoverable hearts.
This Advisory contains statements regarding the clinical trial of the AbioCor and reference to comments made by representatives of Hahnemann University Hospital and they alone are responsible for such comments and the content of their website. Such trials are subject to numerous risks and ABIOMED's actual results may differ materially based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing and other risks detailed in the Company's filings with the Securities and Exchange Commission.
John F. Thero
Chief Financial Officer
Assistant: Christine DeLuca
Sara J. Goldstein
Corporate Communications Specialist